Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir

Clinical Pharmacokinetics

Volumn 54, Issue 7, 2015, Pages 677-690

  Kirby, Brian J ^a   Symonds, William T ^a   Kearney, Brian P ^a   Mathias, Anita A ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; IMMUNOSUPPRESSIVE AGENT; METHADONE; ORAL CONTRACEPTIVE AGENT; RALTEGRAVIR; RIFAMPICIN; RILPIVIRINE; SOFOSBUVIR; NS-5 PROTEIN, HEPATITIS C VIRUS; PRODRUG; VIRUS PROTEIN;

ADVERSE OUTCOME; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; FOOD; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG INTERACTION; HEPATITIS C, CHRONIC; METABOLISM;

ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; HEPATITIS C, CHRONIC; HUMANS; PRODRUGS; SOFOSBUVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84933671704     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0261-7     Document Type: Review

References (37)

1. SOVALDI® (sofosbuvir) tablets, for oral use. US prescribing information [revised]. Foster City: Gilead Sciences, Inc.; 2014.
2. HARVONI® (ledipasvir and sofosbuvir) tablets, for oral use. US prescribing information. Foster City: Gilead Sciences, Inc.; 2014.
3. Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010;285(45):34337–47. doi:10.1074/jbc.M110.161802.
4. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12(3):413–20.
5. Babusis D, Curry MP, Denning J, Wang T, Kirby B, Murakami E, et al. Translational studies to understand the mechanism of liver delivery by sofosbuvir [oral presentation]. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; 19–21 May 2014; Washington, DC.
6. Babusis D, Curry MP, Denning J, Park Y, Murakami E, Afdhal N, et al. Nucleotide analog levels in liver explants from HCV infected subjects undergoing liver transplantation after up to 24 weeks sofosbuvir (GS-7977) with ribavirin treatment [poster no. 1,091]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1–5 Nov 2013; Washington, DC.
7. SOVALDI® (sofosbuvir) tablets, for oral use. EMA summary of product characteristics [revised]. Foster City: Gilead Sciences, Inc.; 2014.
8. Cornpropst M, Denning J, Clemons D, Marbury T, Alcorn H, Smith W, et al. The effect of renal impairment and end stage renal disease on the single-dose pharmacokinetics of GS-7977 [poster no. 1,101]. 47th Annual Meeting of the European Association for the Study of the Liver; 18–22 Apr 2012; Barcelona.
9. Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naive patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial. J Hepatol. 2013;58(4):663–8. doi:10.1016/j.jhep.2012.11.018.
10. Kirby B, Gordi T, Symonds WT, Kearney BP, Mathias A. Population pharmacokinetics of sofosbuvir and its major metabolite (GS-331007) in healthy and HCV-infected adult subjects [poster no. 1,106]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1–5 Nov 2013; Washington, DC.
11. Lawitz E, Rodriguez-Torres M, Denning JM, Albanis E, Cornpropst M, Berrey MM, et al. Pharmacokinetics, pharmacodynamics, and tolerability of GS-9851, a nucleotide analog polymerase inhibitor, following multiple ascending doses in patients with chronic hepatitis C infection. Antimicrob Agents Chemother. 2013;57(3):1209–17. doi:10.1128/AAC.01263-12.
12. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87. doi:10.1056/NEJMoa1214853.
13. Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–77. doi:10.1056/NEJMoa1214854.
14. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370(21):1993–2001. doi:10.1056/NEJMoa1316145.
15. Lawitz E, Rodriguez-Torres M, Cornpropst M, Denning J, Clemons D, McNair L, et al. The effect of hepatic impairment on the safety, pharmacokinetics, and antiviral activity of GS-7977 in hepatitis C infected subjects treated for seven days [poster no. 1,130]. 47th Annual Meeting of the European Association for the Study of the Liver; 18–22 Apr 2012; Barcelona.
16. Gane E, Robson RA, Bonacini M, Maliakkal B, Kirby B, Liu L, et al. Safety, antiviral efficacy, and pharmacokinetics of sofosbuvir in patients with severe renal impairment [abstract no. 966]. 65th Annual Meeting of the American Association for the Study of Liver Diseases; 7–11 Nov 2014; Boston.
17. Mathias A, Cornpropst M, Clemens D, Denning J, Symonds WT. No clinically significant pharmacokinetic drug-drug interactions between sofosbuvir (GS-7977) and the immunosuppressants cyclosporine A or tacrolimus in healthy volunteers [poster no. 1,869]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 9–13 Nov 2012; Boston.
18. Charlton M, Gane E, Manns MP, Brown RS Jr, Curry MP, Kwo PY, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148(1):108–17. doi:10.1053/j.gastro.2014.10.001.
19. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P. Viral hepatitis and HIV co-infection. Antiviral Res. 2010;85(1):303–15. doi:10.1016/j.antiviral.2009.10.021.
20. Limketkai BN, Mehta SH, Sutcliffe CG, Higgins YM, Torbenson MS, Brinkley SC, et al. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA. 2012;308(4):370–8. doi:10.1001/jama.2012.7844.
21. Kirby B, Mathias A, Rossi S, Moyer C, Shen G, Kearney BP. No Clinically significant pharmacokinetic interactions between sofosbuvir (GS-7977) and HIV antiretrovirals atripla, rilpivirine, darunavir/ritonavir, or raltegravir in healthy volunteers [poster no. 1,877]. 63rd Annual Meeting of the American Association for the Study of Liver Diseases; 9–13 Nov 2012; Boston.
22. Sulkowski MS, Naggie S, Lalezari J, Fessel WJ, Mounzer K, Shuhart M, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312(4):353–61. doi:10.1001/jama.2014.7734.
23. ATRIPLA® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) tablets. US prescribing information. Foster City: Gilead Sciences and Bristol-Myers Squibb, LLC; 2012.
24. Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther. 2002;72(1):1–9. doi:10.1067/mcp.2002.124519.
25. Tong L, Phan TK, Robinson KL, Babusis D, Strab R, Bhoopathy S, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51(10):3498–504. doi:10.1128/AAC.00671-07.
26. German P, Warren D, West S, Hui J, Kearney BP. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancer-containing single-tablet fixed-dose combination regimen for the treatment of HIV. J Acquir Immune Defic Syndr. 2010;55(3):323–9. doi:10.1097/QAI.0b013e3181eb376b.
27. EDURANT® (rilpivirine) tablets. US prescribing information. Raritan: Tibotec Pharmaceuticals; 2011.
28. ISENTRESS® (raltegravir) film-coated tablets, for oral use, ISENTRESS® (raltegravir) chewable tablets, for oral use. US prescribing information [revised]. Whitehouse Station: Merck & Co., Inc.; 2012.
29. Hanley WD, Wenning LA, Moreau A, Kost JT, Mangin E, Shamp T, et al. Effect of tipranavir–ritonavir on pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009;53(7):2752–5. doi:10.1128/AAC.01486-08.
30. Iwamoto M, Wenning LA, Petry AS, Laethem M, De Smet M, Kost JT, et al. Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2008;52(12):4338–43. doi:10.1128/AAC.01543-07.
31. Martinez AD, Dimova R, Marks KM, Beeder AB, Zeremski M, Kreek MJ, et al. Integrated internist—addiction medicine—hepatology model for hepatitis C management for individuals on methadone maintenance. J Viral Hepat. 2012;19(1):47–54. doi:10.1111/j.1365-2893.2010.01411.x.
32. Boulton DW, Arnaud P, DeVane CL. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate. Clin Pharmacol Ther. 2001;70(1):48–57. doi:10.1067/mcp.2001.116793.
33. Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol. 1997;17(2):113–7.
34. Eap CB, Cuendet C, Baumann P. Binding of d-methadone, l-methadone, and dl-methadone to proteins in plasma of healthy volunteers: role of the variants of alpha 1-acid glycoprotein. Clin Pharmacol Ther. 1990;47(3):338–46.
35. Denning J, Cornpropst M, Clemons D, Fang L, Sale M, Berrey M, et al. Lack of effect of the nucleotide analog polymerase inhibitor PSI-7977 on methadone pharmacokinetics and pharmacodynamics [abstract no. 372]. 62nd Annual Meeting of the American Association for the Study of Liver Diseases; 4–8 Nov 2011; San Francisco.
36. German P, Moorehead L, Pang PS, Vimal M, Mathias A. Lack of a clinically important pharmacokinetic interaction between norgestimate/ethinyl estradiol and sofosbuvir (SOF) or ledipasvir (LDV) in HCV-uninfected female subjects [poster no. 469]. 64th Annual Meeting of the American Association for the Study of Liver Diseases; 1–5 Nov 2011; Washington, DC.
37. ORTHO TRI-CYCLEN® Lo Tablets (norgestimate/ethinyl estradiol). US prescribing information [revised]. Manati: Janssen Ortho, LLC.; 2012.